ArticleJournal for immunotherapy of cancer2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data.
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Balancing immunosuppression and cancer survival in the treatment of immune checkpoint inhibitor-associated inflammatory arthritis.EULAR rheumatology open · 2026Review
- Health care use and costs associated with clinically impactful immune-related adverse events during immune checkpoint inhibitor therapy for non-small cell lung cancer.Journal of managed care & specialty pharmacy · 2026Article
- Overlapping Toxicities of Pembrolizumab and Lenvatinib: A Case of Capillary Leak Syndrome with Severe Erythroblastosis.Current oncology (Toronto, Ont.) · 2026Article
- Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study.Cancers · 2026Article
- An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation study.medRxiv : the preprint server for health sciences · 2026Article
- Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2025Article
- Real-world management and outcomes of immune-related adverse events in German cancer care: A multicenter analysis using the SERIO registry.The oncologist · 2025Article
- Development of a predictive model for immune‑related adverse events in patients with cancer.Oncology letters · 2025Article
- Reporting of immune-related adverse events in US Food and Drug Administration approvals of immune checkpoint inhibitors.Frontiers in oncology · 2025Article
- Onco-rheumatology: from rags to riches, a transdisciplinary evolution.Rheumatology advances in practice · 2025Article
- Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Navigating the Complexities of Artificial Intelligence-Enabled Real-World Data Collection for Oncology Pharmacovigilance.JCO clinical cancer informatics · 2024Article
- Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.JCO clinical cancer informatics · 2024Article
- Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.Journal for immunotherapy of cancer · 2024Article
- Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.Journal for immunotherapy of cancer · 2024Article
- Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing.JCO clinical cancer informatics · 2024Article
- Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.The oncologist · 2024Article
- Review
- Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes.International journal of clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer therapy, such as chemotherapy, radiotherapy, or targeted therapy, is also expanding. However, immune-related adverse events (irAEs) can be serious in up to a third of patients. Critical questions remain surrounding the characteristics and outcomes of irAEs, and how they may affect the overall risk-benefit relationship for combination therapies. This article proposes a framework for irAE classification and reporting, and identifies limitations in the capture and sharing of data on irAEs from current clinical trial and real-world data. We outline key gaps and suggestions for clinicians, clinical investigators, drug sponsors, patients, and other stakeholders to make these critical data more available to researchers for pooled analysis, to advance contemporary understanding of irAEs, and ultimately improve the efficacy of ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.